Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ATP4A | P20648 | 1/20 | 0.41 |
| ▸ | ATP4B | P51164 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697436 | 0.81 | TDO2 (0.61) | TDO2 | |
| SCHEMBL18509943 | 0.80 | MEN1 (0.53) | TDO2MEN1KMT2ANR4A2HTR2A | |
| SCHEMBL16698347 | 0.78 | DYRK1A (0.59) | TDO2MEN1KMT2APIM1PIM3 | |
| SCHEMBL21892784 | 0.77 | IMPDH2 (0.58) | TDO2MEN1KMT2ANR4A2HTR2A | |
| SCHEMBL16697582 | 0.77 | IMPDH2 (0.59) | TDO2PIM1PIM3PIM2NR4A2 | |
| SCHEMBL29563848 | 0.77 | IMPDH2 (0.59) | TDO2PIM1PIM3PIM2NR4A2 | |
| SCHEMBL16697445 | 0.74 | TDO2 (0.57) | TDO2PIM1PIM3PIM2CHUK | |
| SCHEMBL28160319 | 0.74 | PIM1 (0.52) | TDO2MEN1KMT2APIM1PIM3 | |
| SCHEMBL31517778 | 0.74 | TDO2 (0.60) | TDO2MEN1KMT2ANR4A2 | |
| SCHEMBL16596104 | 0.74 | DYRK1A (0.70) | TDO2PIM1HTR2AIMPDH2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9126984-B2 | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS SA (BE) | 2015-09-08 | — | — | US | disclosed |
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS SA (BE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | TDO2 1/4885MEN1 4785/4885KMT2A 2859/4885 |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | TDO2 1/4885MEN1 4783/4885KMT2A 3622/4885 |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | TDO2 1/4885MEN1 4765/4885KMT2A 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.